This strategic alliance is aimed at strengthening hospital systems and developing advanced AMR interventions
If approved, Blenrep (belantamab mafodotin) in combinations with BorDex (BVd) and PomDex (BPd) could redefine multiple myeloma treatment at or after first relapse
Performed within GENEWIZ from Azenta Life Sciences' CLIA-certified and CAP-accredited state-of-the-art clinical genomics laboratory
Emcure has launched an awareness campaign to help spread the word about male anemia
HYMPAVZI’s approval is based on Phase 3 study results demonstrating non-inferiority and superiority compared to routine prophylaxis in eligible patients with hemophilia A or B without inhibitors
With 6 operation hubs and 18 offices across North America, Europe, and Asia, Indegene’s client base includes the world’s top 20 biopharma companies
Modernization and supply chain diversity drive new growth
Recommendation based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival to more than three years
Subscribe To Our Newsletter & Stay Updated